Seattle biotechnology start-up Blaze Bioscience has raised .5 million to continue developing technologies that are designed to help surgeons more easily identify cancer cells in the body. Total funding in the company now stands at .8 million. Blaze said that the money came from individual investors, including doctors and biotech execs.
